Importance of the relationship between symptoms and self-reported physical activity level in stable COPD based on the results from the SPACE study.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
14 May 2019
Historique:
received: 26 11 2018
accepted: 16 04 2019
entrez: 16 5 2019
pubmed: 16 5 2019
medline: 25 12 2019
Statut: epublish

Résumé

The burden of symptoms and risk of exacerbations are the main drivers of the overall assessment of the Chronic Obstructive Pulmonary Disease (COPD) and the adequate treatment approaches per current Global Initiative for Chronic Obstructive Lung Disease (GOLD). Physical activity has emerged as both functional outcome and non-pharmacological intervention in COPD patients, despite the lack of standardized measures or guidelines in clinical practice. This study aimed to explore in more depth the 24-h respiratory symptoms, the physical activity level (PAL) and the relationship between these two determinants in stable COPD patients. This was a multinational, multicenter, observational, cross-sectional study conducted in ten European countries and Israel. Dedicated questionnaires for each part of the day (morning, daytime, night) were used to assess respiratory symptoms. PAL was evaluated with self- and interview-reported tools [EVS (exercise as vital sign) and YPAS (Yale Physical Activity Survey)], and physician's judgement. Patients were stratified in ABCD groups by 2013 and 2017 GOLD editions using the questionnaires currently recommended: modified Medical Research Council dyspnea scale and COPD Assessment Test. The study enrolled 2190 patients (mean age: 66.9 years; male: 70.0%; mean % predicted FEV1: 52.6; GOLD groups II-III: 84.5%; any COPD treatment: 98.9%). Most patients (> 90%) reported symptoms in any part of the 24-h day, irrespective of COPD severity. PAL evaluations showed discordant results between patients and physicians: 32.9% of patients considered themselves completely inactive, while physicians judged 11.9% patients as inactive. By YPAS, the overall study population spent an average of 21.0 h/week performing physical activity, and 68.4% of patients were identified as sedentary. In any GOLD ABCD group, the percentage of inactive patients was high. Our study found negative, weak correlations between respiratory symptoms and self-reported PAL (p < 0.001). Despite regular treatment, the majority of stable COPD patients with moderate to severe disease experienced daily variable symptoms. Physical activity level was low in this COPD cohort, and yet overestimated by physicians. With evidence indicating the negative consequences of inactivity, its adequate screening, a more active promotion and regular assessment of physical activity are urgently needed in COPD patients for better outcomes. NCT03031769 , retrospectively registered, 23 Jan 2017.

Sections du résumé

BACKGROUND BACKGROUND
The burden of symptoms and risk of exacerbations are the main drivers of the overall assessment of the Chronic Obstructive Pulmonary Disease (COPD) and the adequate treatment approaches per current Global Initiative for Chronic Obstructive Lung Disease (GOLD). Physical activity has emerged as both functional outcome and non-pharmacological intervention in COPD patients, despite the lack of standardized measures or guidelines in clinical practice. This study aimed to explore in more depth the 24-h respiratory symptoms, the physical activity level (PAL) and the relationship between these two determinants in stable COPD patients.
METHODS METHODS
This was a multinational, multicenter, observational, cross-sectional study conducted in ten European countries and Israel. Dedicated questionnaires for each part of the day (morning, daytime, night) were used to assess respiratory symptoms. PAL was evaluated with self- and interview-reported tools [EVS (exercise as vital sign) and YPAS (Yale Physical Activity Survey)], and physician's judgement. Patients were stratified in ABCD groups by 2013 and 2017 GOLD editions using the questionnaires currently recommended: modified Medical Research Council dyspnea scale and COPD Assessment Test.
RESULTS RESULTS
The study enrolled 2190 patients (mean age: 66.9 years; male: 70.0%; mean % predicted FEV1: 52.6; GOLD groups II-III: 84.5%; any COPD treatment: 98.9%). Most patients (> 90%) reported symptoms in any part of the 24-h day, irrespective of COPD severity. PAL evaluations showed discordant results between patients and physicians: 32.9% of patients considered themselves completely inactive, while physicians judged 11.9% patients as inactive. By YPAS, the overall study population spent an average of 21.0 h/week performing physical activity, and 68.4% of patients were identified as sedentary. In any GOLD ABCD group, the percentage of inactive patients was high. Our study found negative, weak correlations between respiratory symptoms and self-reported PAL (p < 0.001).
CONCLUSIONS CONCLUSIONS
Despite regular treatment, the majority of stable COPD patients with moderate to severe disease experienced daily variable symptoms. Physical activity level was low in this COPD cohort, and yet overestimated by physicians. With evidence indicating the negative consequences of inactivity, its adequate screening, a more active promotion and regular assessment of physical activity are urgently needed in COPD patients for better outcomes.
TRIAL REGISTRATION BACKGROUND
NCT03031769 , retrospectively registered, 23 Jan 2017.

Identifiants

pubmed: 31088560
doi: 10.1186/s12931-019-1053-7
pii: 10.1186/s12931-019-1053-7
pmc: PMC6518503
doi:

Banques de données

ClinicalTrials.gov
['NCT03031769']

Types de publication

Clinical Trial Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

89

Subventions

Organisme : AstraZeneca Europe
ID : Not applicable

Références

Thorax. 1999 Jul;54(7):581-6
pubmed: 10377201
J Sports Med Phys Fitness. 2001 Dec;41(4):479-85
pubmed: 11687767
Eur Respir J. 2009 Feb;33(2):262-72
pubmed: 19010994
Respir Med. 2009 May;103(5):692-9
pubmed: 19131231
Eur Respir J. 2009 Feb;33(2):227-9
pubmed: 19181910
Med Sci Sports Exerc. 2009 May;41(5):998-1005
pubmed: 19346988
Curr Med Res Opin. 2009 Aug;25(8):2043-8
pubmed: 19569976
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
Eur J Cardiovasc Prev Rehabil. 2010 Apr;17(2):127-39
pubmed: 20215971
Med Sci Sports Exerc. 2011 Feb;43(2):218-24
pubmed: 20543752
Eur Respir J. 2011 Feb;37(2):264-72
pubmed: 21115606
Respir Res. 2011 Mar 22;12:33
pubmed: 21426563
Eur Respir J. 2012 Jan;39(1):38-45
pubmed: 21737561
Lancet. 2011 Oct 1;378(9798):1244-53
pubmed: 21846575
Arch Bronconeumol. 2011 Nov;47(11):552-60
pubmed: 21975081
Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61
pubmed: 22561964
Med Sci Sports Exerc. 2012 Nov;44(11):2071-6
pubmed: 22688832
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Chron Respir Dis. 2013 Feb;10(1):19-27
pubmed: 23149382
Arch Phys Med Rehabil. 2013 Dec;94(12):2396-2402.e7
pubmed: 23872081
Respir Res. 2013 Oct 21;14:112
pubmed: 24143997
Prim Care Respir J. 2013 Dec;22(4):425-30
pubmed: 24217860
J Gen Intern Med. 2014 Feb;29(2):341-8
pubmed: 24309950
Am Fam Physician. 2013 Nov 15;88(10):655-63, 663B-F
pubmed: 24364481
Thorax. 2014 Aug;69(8):731-9
pubmed: 24558112
Thorax. 2014 May;69(5):443-9
pubmed: 24595666
BMC Pulm Med. 2014 Jun 02;14:98
pubmed: 24885188
Int J Chron Obstruct Pulmon Dis. 2014 Jun 04;9:577-88
pubmed: 24940054
Respir Res. 2014 Oct 21;15:122
pubmed: 25331383
Eur Respir J. 2014 Dec;44(6):1521-37
pubmed: 25359358
Int J Chron Obstruct Pulmon Dis. 2014 Dec 12;9:1377-88
pubmed: 25548519
Respirology. 2015 Apr;20(3):413-8
pubmed: 25565363
Int J Chron Obstruct Pulmon Dis. 2015 Mar 06;10:475-87
pubmed: 25834415
Int J Chron Obstruct Pulmon Dis. 2015 Mar 17;10:577-86
pubmed: 25844033
Am J Respir Crit Care Med. 2015 Oct 15;192(8):924-33
pubmed: 26161676
Am J Respir Crit Care Med. 2015 Aug 1;192(3):267-9
pubmed: 26230227
Respir Med. 2015 Oct;109(10):1320-5
pubmed: 26298024
BMJ Open. 2016 Apr 13;6(4):e010106
pubmed: 27075841
Respiration. 2016;92(2):72-9
pubmed: 27404667
NPJ Prim Care Respir Med. 2016 Jul 21;26:16040
pubmed: 27442618
Med Clin (Barc). 2017 Feb 9;148(3):114-117
pubmed: 27993404
Eur Respir Rev. 2017 Jan 3;26(143):
pubmed: 28049127
Respir Med. 2017 Aug;129:165-172
pubmed: 28732827
Chron Respir Dis. 2017 Aug;14(3):231-244
pubmed: 28774202
Int J Chron Obstruct Pulmon Dis. 2017 Aug 24;12:2545-2558
pubmed: 28883722
Respir Med. 2018 Jan;134:62-69
pubmed: 29413510
PeerJ. 2018 Apr 27;6:e4604
pubmed: 29719731
BMC Pulm Med. 2018 Jun 7;18(1):98
pubmed: 29879930
ERJ Open Res. 2018 Aug 03;4(3):null
pubmed: 30083551
Med Sci Sports Exerc. 1993 May;25(5):628-42
pubmed: 8492692

Auteurs

Florin Mihaltan (F)

Department of Pulmonology, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania. mihaltan@starnets.ro.

Yochai Adir (Y)

Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Adam Antczak (A)

Clinical Department of Pulmonology and Allergology, University Hospital, Lodz, Poland.

Konstantinos Porpodis (K)

Thessaloniki University Medical School, Thessaloniki, Greece.

Vesna Radulovic (V)

Municipal Institute for Lung Diseases and Tuberculosis, Belgrade, Serbia.

Nuno Pires (N)

Hospital Santa Maria Maior, Barcelos, Portugal.

Geeuwke Jan de Vries (GJ)

Zuyderland Ziekenhuis Sittard, Geleen, Netherlands.

Andreas Horner (A)

Kepler University Hospital, Krankenhausstrasse 9, A4021, Linz, Austria.

Samuel De Bontridder (S)

UZ Brussel, Laarbeeklaan 101, 1090, Jette, Belgium.

Yunqin Chen (Y)

AstraZeneca Global R&D Information, Shanghai, China.

Anat Shavit (A)

AstraZeneca Germany, Wedel, Germany.

Silviu Alecu (S)

AstraZeneca Romania, Bucharest, Romania.

Lukasz Adamek (L)

AstraZeneca Europe, Luton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH